raised, for the second time, its 2014 guidance by a big margin. The Company Biogen Idec is one of the world's leading biotechnology companies. Biogen discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis
get on a regular basis is what do I look for when identifying and purchasing off the radar small cap stocks especially in the biotech sector especially given a recent big win on a previously highlighted small cap play (See below). This makes sense as nothing
Incyte is mentioned frequently as an acquisition target. Whether Incyte gets acquired or not it is still a very compelling biotech investment with growing sales, a deep pipeline with important catalysts approaching. Let's take a closer look... SALES
Horizon Pharma (NASDAQ: HZNP ) shareholders approve its acquisition of Irish biotech Vidara Therapeutics. It plans to shift its domicile to Ireland today making it the first U.S. company to complete a tax inversion deal. Post your comment!
Presentation Steve Byrne - Bank of America Merrill Lynch Well welcome to the last session of the day. My name is Steve Byrne. I am a Biotech Analyst for BofA Merrill in New York. And it’s a pleasure for me to host Orexigen. Mark Booth, Chief Commercial Officer
By Andy Batts : Oncolytics Biotech (NASDAQ: ONCY ) announced overall and KRAS-mutated patient data from its Phase II pancreatic cancer study. It was a two
Two new biotechs open with strong up moves today: Foamix Pharmaceuticals (NASDAQ: FOMX ) is up 16% from its $6 offer price on turnover of 13M shares. ProQR Therapeutics (NASDAQ: PRQR ) is up 32% from its $13 offer price on turnover of 5.5M shares. Post your comment!
NASDAQ: GILD ) . The shares have had a big run since all biotech stocks had a "hiccup" in early March. However, they have ..... to have incited some trepidation among shareholders in this biotech juggernaut. (click to enlarge) These concerns appear to
Inc. (NASDAQ: GILD ) is one of the best performers in the biotech industry. Gilead's shares have risen by an astonishing ..... outpacing both the S&P 500 Index's 10% return and the Nasdaq Biotechnology Index's 19% return. This extraordinary performance is
Pharmaceuticals (NASDAQ: RXII ) is an up-and-coming biotechnology company that has recently caught my eye after losing 40 ..... huge risks in investing in the small developmental-stage biotechnology companies. The pain of losing 40% is very real. But